Multiple organ infection and the pathogenesis of SARS

Jiang Gu, Encong Gong, Bo Zhang, Jie Zheng, Zifen Gao, Yanfeng Zhong, Wanzhong Zou, Jun Zhan, Shenglan Wang, Zhigang Xie, Hui Zhuang, Bingquan Wu, Haoao Zhong, Hongquan Shao, Weigang Fang, Dongshia Gao, Fei Pei, Xingwang Li, Zhongpin He, Dazhen Xu, Xeying Shi, Virginia M. Anderson, and Anthony S.-Y. Leong

1Department of Pathology and 2Department of Microbiology, Peking University, Beijing, China 100083
3Beijing Ditan Hospital, Beijing, China 100011
4State University of New York Health Science Center at Brooklyn, Brooklyn, NY 11203
5Hunter Area Pathology Services and Discipline of Anatomical Pathology, University of Newcastle, Newcastle, Australia 2310

After >8,000 infections and >700 deaths worldwide, the pathogenesis of the new infectious disease, severe acute respiratory syndrome (SARS), remains poorly understood. We investigated 18 autopsies of patients who had suspected SARS; 8 cases were confirmed as SARS. We evaluated white blood cells from 22 confirmed SARS patients at various stages of the disease. T lymphocyte counts in 65 confirmed and 35 misdiagnosed SARS cases also were analyzed retrospectively. SARS viral particles and genomic sequence were detected in a large number of circulating lymphocytes, monocytes, and lymphoid tissues, as well as in the epithelial cells of the respiratory tract, the mucosa of the intestine, the epithelium of the renal distal tubules, the neurons of the brain, and macrophages in different organs. SARS virus seemed to be capable of infecting multiple cell types in several organs; immune cells and pulmonary epithelium were identified as the main sites of injury. A comprehensive theory of pathogenesis is proposed for SARS with immune and lung damage as key features.

The target organ of severe acute respiratory syndrome (SARS) is widely believed to be the lungs, hence the names “severe acute respiratory syndrome” and “SARS atypical pneumonia” (1, 2). However, patients often have evidence of other organ dysfunction, including gastrointestinal symptoms (3), abnormal liver function (4, 5), splenic atrophy, and lymphadenopathy (6). This may reflect widespread immunopathology or the presence of extrapulmonary SARS-coronavirus (CoV) dissemination and replication, as has been observed in other species infected with animal coronavirus (7). Recent reports of multiple organ infection by the virus were based mostly on partial autopsies (8). A comprehensive theory of pathogenesis for this newly emerged infectious disease is lacking.

We report here on our postmortem study of 18 patients who had suspected SARS who died 14–62 d after the onset of symptoms. In addition, blood samples were examined from 22 cases of confirmed SARS, 3–29 d after the onset of symptoms. We also investigated the immune cell lesion in 100 patients who had suspected SARS who were admitted to our hospitals; 35 were found retrospectively to have been misdiagnosed. We set out to verify a hypothesis of immune cell injury–based damage for the pathogenesis of SARS. Analysis of our newly obtained histologic and molecular data, and clinical information revealed a more complete picture of the infection.

RESULTS

8 of the 18 suspected SARS victims were confirmed as having SARS by demonstration of the pathogen with real-time RT-PCR, in situ hybridization, and electron microscopy (EM). All cases had similar pathologic changes in their lungs, immune system, and other organs. Differences in the severity of pathologic changes were noted among SARS cases, which varied with the duration of the disease before death. The examination of the blood samples from patients who had early-stage SARS provided insights into the pathologic changes at the early phase of the disease. Dis-
distinct differences in lymphocyte counts between confirmed and misdiagnosed cases also were demonstrated. These are reported in the following text.

Figure 1. SARS pathology in the respiratory tract. (A) Lung of a SARS victim. The cut surface showed severe edema, consolidation, and hemorrhage. (B) LM of hematoxylin and eosin preparation of a SARS lung. The interstitial tissue was thickened with fibrin exudation and organization. Many alveoli were collapsed, filled with fluid, and exhibited hyaline membranes. Cellular infiltration was not obvious. Bar, 50 μm. (C) In situ hybridization of SARS genomic sequence of the lung from a SARS victim who died 62 d after the onset of high fever detected a large number of pulmonary epithelial cells (small arrows) that contained the virus. Multinuclear giant syncytial cells found in the alveoli contained a number of pulmonary epithelial cells (small arrows) that contained the SARS victim who died 62 d after the onset of high fever detected a large (C) In situ hybridization of SARS genomic sequence of the lung from a SARS victim who died 62 d after the onset of high fever detected a large amount of SARS viral sequences (large arrows). Bar, 80 μm. (D) In situ hybridization of SARS genomic sequence of the lung from a SARS victim who died 35 d after the initial symptoms showed macrophages (large arrows) in an alveolus, and many pulmonary epithelial cells (small arrows) contained the virus. Bar, 100 μm. (E) Blood vessel in SARS lung—double labeling, immunohistochemistry of CD68—brown (thin arrows). In situ hybridization of SARS viral sequence—black (thick arrows). A mixed color (arrowheads) indicates that monocyte was infected by SARS virus. The black color also may overshadow the brown color when both are present in the same blood cells and the in situ hybridization signal is very strong. Bar, 100 μm. (F) Negative control for in situ hybridization of SARS genomic sequence of the lung. No positive signal was detected. Bar, 100 μm. (G) EM in situ hybridization with colloidal gold labeling (10 nm gold; arrows) of viral sequence demonstrated that type II epithelial cells of the lung contained the virus. Bar, 0.2 μm. (H) EM image of a portion of an epithelial cell in the lung of a patient who had SARS. The region indicated by the arrow is enlarged in I. Bar, 2 μm. (I) Enlargement of the region in H. A large number of SARS virus–like particles (arrows) was observed. Bar, 0.5 μm. (J) In situ hybridization of SARS viral sequence demonstrated that most of the ciliated epithelial cells (arrows) of the trachea from a patient who had SARS were infected by the virus. Bar, 50 μm. (K) Negative control for in situ hybridization of SARS genomic sequence of the trachea from a patient who had SARS. No positive signal was detected. Bar, 50 μm.

Respiratory tract
The affected lungs showed severe consolidation with tissue consistency approximating that of the liver (Fig. 1 A). The SARS lungs were, on average, three to four times heavier than normal lungs. Conventional light microscopy (LM) demonstrated widespread damage of the lung parenchyma, with extensive fibrin exudate, edema, interstitial thickening, and extensive hyaline membrane formation (Fig. 1 B). There was extensive alveolar collapse, and the remaining alveoli were filled with fluid and desquamated alveolar and bronchial epithelial cells. Alveolar epithelial hyperplasia was evident. Large syncytial cells with multiple nuclei were present. Small vessel vasculitis was seen. However, cellular infiltrate was rare and conspicuously absent in most cases, and lymphocytic infiltration was sparse. Overall, the diffuse alveolar damage resembled that seen in adult respiratory distress syndrome, but with a paucity of inflammatory infiltrate.

In situ hybridization demonstrated SARS viral sequences in the cytoplasm of a large number of intact and degenerating epithelial cells of the lungs as well as in the scanty infiltrating lymphocytes and clustered macrophages (Fig. 1, C and D). Pulmonary epithelial cells were identified with immunostaining using antibodies to AE1 and AE3. The giant syncytial cells were particularly rich in hybridization signals. Monocytes and lymphocytes in blood vessels of the lungs also were positive for in situ hybridization (Fig. 1 E). Negative control for in situ hybridization of SARS genomic sequence of the lung showed no positive signal when an unrelated probe was used (Fig. 1 F). EM demonstrated SARS–like viral particles in the cytoplasm of the epithelial cells (Fig. 1, H and I). In situ hybridization with specific probes, and colloid gold–labeled secondary antibodies detected specific positive signals in the cytoplasm of epithelial cell types I and II at the EM level (Fig. 1 G). Double labeling of SARS–infected cells with in situ hybridization and cytokeratin immunolabeling revealed that pulmonary epithelial cells were infected by SARS virus. The proliferative cells in the lungs were mainly type II cells as evidenced by their LM morphology.

SARS viral sequences also were detected in the epithelial cells of the trachea, bronchi, and bronchioles by in situ hybridization (Fig. 1 J). More than 50% of ciliated epithelial cells in the trachea displayed positive cytoplasmic in situ hybridization; no positive signal was detected in the negative control when an unrelated probe was used (Fig. 1 K).

Table I. Percent of granulocytes, monocytes, and lymphocytes in SARS and control patients

|                | No. of cases | No. of granulocytes | No. of monocytes | No. of lymphocytes |
|----------------|--------------|---------------------|------------------|--------------------|
| Normal         | 4            | 66.5 ± 4.8          | 8.8 ± 1.4        | 24.8 ± 2.3         |
| SARS           | 6            | 83.2 ± 6.9          | 6.2 ± 0.9        | 10.7 ± 1.0         |

*P < 0.01 compared with normal.

*P < 0.05 compared with normal.
Figure 2. SARS pathology in the immune system. (A) EM image of a circulating T lymphocyte in a patient who had SARS 6 d after onset of fever. Bar, 2 μm. Inset: A higher power view of the region in panel A. A group of SARS coronavirus-like particles was located in the cytoplasm. Bar, 0.2 μm. (B) EM image of the cytoplasm of a lymphocyte showing three coronavirus-like particles (arrows) in the cytoplasm. The lower two are located near the cell membrane. The one on the lower left seems to have just trespassed the membrane and entered the lymphocyte. Bar, 0.5 μm. Inset: A higher power EM image of the membrane region of a peripheral lymphocyte. A coronavirus-like particle (arrow) is shown entering the target cell, and the cell membrane still fused with the viral envelope. E, extracellular space. Bar, 0.1 μm. Similar SARS coronavirus-like particles were not detected in the lymphocytes of non-SARS patient (not depicted). (C) LM hematoxylin and eosin staining of the spleen from a patient who had SARS showing depletion of periarterial lymphatic sheath and dilation of splenic sinusoid. No splenic corpuscle was preserved. Bar, 200 μm. (D) LM immunohistochemistry staining of the spleen from a misdiagnosed patient shows the normal distribution and size of CD68+ macrophages. Bar, 20 μm. (E) LM immunohistochemistry staining of the spleen from a patient who had confirmed SARS shows that CD68+ macrophages are larger than those in the misdiagnosed case. Bar, 20 μm. (F) Negative control for immunohistochemistry staining of the spleen from a patient who had confirmed SARS in which PBS was substituted for the anti-CD68 antibody. No positive signal was detected. Bar, 20 μm. (G) In situ hybridization detected SARS genomic sequence positive lymphocytes (arrows) in the spleen from a SARS autopsy. Bar, 70 μm. (H) In situ hybridization detected SARS genomic sequence positive lymphocytes (arrows) in a lymph node from the hilus of the lung of a SARS autopsy. Bar, 70 μm. (I) Negative control for in situ hybridization of SARS genomic sequence of the lymphocytes in the spleen from a SARS autopsy, in which an unrelated probe was used. No positive signal was detected. Bar, 100 μm. (J) In situ hybridization detected SARS genomic sequence positive lymphocytes in the vessel of thyroid gland from a SARS autopsy. Bar, 70 μm. (K) Negative control for in situ hybridization of SARS genomic sequence, in which the specific probe was substituted by an unrelated probe, of the lymphocytes in thyroid gland of a SARS autopsy. No positive signal was detected. Bar, 70 μm. (L) Spleen of a 51-yr-old male patient who had SARS. The spleen was atrophic with a wrinkled capsule. The texture was very soft. LM revealed marked depletion of the lymphoid population in the spleen. (M) In situ hybridization detected SARS genomic sequence positive lymphocytes (arrows) in a lymph node dissected from the mesentery of a SARS autopsy. Bar, 50 μm.

Table II. Percent of white blood cells containing coronavirus-like particles in SARS patients (n = 6)

|                | Total cells | Cells with virus particles | Positive cells |
|----------------|-------------|----------------------------|----------------|
|               | mean ± SEM  | mean ± SEM                 | %              |
| Granulocytes  | 83.2 ± 6.3  | 2.5 ± 0.4                  | 3.0            |
| Monocytes     | 6.2 ± 0.9   | 1.8 ± 0.4                  | 29.7           |
| Lymphocytes   | 10.7 ± 1.0  | 5.5 ± 0.7                  | 51.5           |

Immune cells

Among the 22 SARS blood samples that were obtained from the early stages of the disease, EM detected SARS-like viral particles in monocytes and lymphocytes of six patients. These round viral particles, with diameters of 80–120 nm, were located in the cytoplasm. The particles had double membranes and pale cores with short processes that projected outward. The percentage of total circulating lymphocytes was decreased (Table I). The percentages of different cell types that harbored SARS-like viral particles are shown in Table II. Positive samples included those taken within 10 d of the onset of fever, and in one instance as early as 3 d. Most of the infected cells were T cells. Some B cells and NK cells also were infected by the virus. By EM, the viral particles tended to form clusters and were located within or near the endoplasmic reticulum. T lymphocytes were identified by their unique morphology with a size of ~8–15 μm in diameter; round shape with irregular cell membranes and small villous processes; large rounded, but sometimes, irregular nucleus; and small quantities of cytoplasm devoid of lysosomes. Labeling of these cells with antibody to CD3 and pre-embedding immunoperoxidase labeling for EM further confirmed the nature of these cells. The macrophages appeared to be activated as they became slightly larger. The nature of these cells was confirmed with immunohistochemistry of CD68.

In the autopsy samples, in situ hybridization and EM demonstrated virus–infected immune cells in the circulating blood, spleen, lymph nodes, and lymphoid tissue of various organs. A large proportion of lymphocytes in the circulation and lymphoid organs contained the virus (Fig. 2, A and B). The spleen and lymph nodes were atrophic (Fig. 2 L). The average weight of the spleen was 62% of that of controls and unconfirmed cases. LM with hematoxylin and eosin staining revealed a notable decrease of lymphocytes in these organs (Fig. 2 C). Immunolabeling with seven markers was
undertaken to identify seven cell types (Table III). All immune cell types, including dendritic cells, were decreased significantly (P < 0.01), and CD68 positive macrophages, which were decreased in number, were noticeably (P < 0.01) increased in size and gave the impression of macrophage activation (Fig. 2, D and E). In the negative control for immunohistochemistry of spleens from confirmed SARS patients in which PBS was substituted for the anti-CD68 antibody, no positive signal was detected (Fig. 2 F). In situ hybridization identified the SARS viral sequence in the enlarged macrophages and in the isolated and sometimes clustered T lymphocytes, which were distributed mostly at the periphery of the germinal centers of the splenic white pulp, lymph nodes, and peripheral blood (Fig. 1 E; Fig. 2 G, H, J, and M).

The lymphoid component of the intestine showed widespread degenerative changes. The lymphoid follicles (Peyer’s patches) showed markedly decreased lymphocytes (Fig. 3 A), and in severe cases only the depleted stromal framework of the structure remained. EM detected viral particles in the submucosa of the gut (Fig. 3, B and C) and within the residual lymphocytes. In situ hybridization demonstrated the presence of SARS positivity in the lymphocytes of the mucosa and the submucosa (Fig. 3 D). Positive signal was not found in the negative control, in which no specific probe were used, or in the non-SARS cases (Fig. 3, E and F).

**Digestive tract**

In all of the confirmed SARS cases, the digestive tract displayed mild inflammatory changes. The most obvious lesions in the digestive tract were the deletions of the submucosa lymphoid tissues described above (Fig. 3 A). In addition, the epithelial cells of mucosa of the small and large intestines were found to be infected by the virus by in situ hybridization and EM (Fig. 3 G). Similar positive cells were not found in the stomach or the esophagus. Detailed descriptions of gastrointestinal involvement in SARS are reported separately (9). Such positive reaction was not seen in the negative controls—in which no specific probe was used—or in the non-SARS cases (Fig. 3, H and I).

**Kidneys**

The kidneys were focally hemorrhagic. In situ hybridization localized viral sequences to the epithelial cells of the renal distal tubules (Fig. 3 J). Clusters of SARS viral particles also were detected in the cytoplasm of the distal tubular epithelium by EM (Fig. 3, M and N). The specificity of the above reactions was established with the negative controls (Fig. 3, K and L).

**Brain**

SARS genome sequences were detected in the brain of all SARS autopsies with LM, EM, and with real-time RT-PCR. The signals were confined to the cytoplasm of numerous neurons in the hypothalamus and cortex (Fig. 3 O). Edema and scattered red degeneration of the neurons were present in the brains of six of the eight confirmed cases of SARS. SARS viral sequences and pathologic changes were not present in the brains of unconfirmed cases or control cases (Fig. 3, P and Q).

**Other organs**

In five out of the eight confirmed cases, hepatocytes in the centrilobular zone showed apparent degenerative changes. The testes of the seven male patients displayed focal atrophy. However, SARS viral sequences and viral particles were not identified in the parenchymal cells by in situ hybridization or EM in these organs. No obvious pathologic change was observed in the heart, the pancreas, the adrenal gland, the thyroid gland, or the skeletal muscle, although SARS-harboring lymphocytes and monocytes were found in some of these organs, mostly within vessels. Tissue samples from the mouth, the nasal mucosa, and the bone marrow were not available for examination.

**T lymphocyte counts**

Retrospective analyses revealed significant differences in T lymphocyte subtypes in blood samples that were collected at different time points from the onset of the disease in confirmed SARS patients versus misdiagnosed cases (P < 0.05; Fig. 4). T lymphocytes (CD3⁺, CD4⁺, and CD8⁺ cells) were decreased at the onset of symptoms; this decrease persisted until the recovery phase. When glucocorticoids were administered, the lymphocytes were decreased further in both groups of patients; however, the difference in lymphocyte counts between the SARS and non-SARS cases persisted. The differences in other blood cell types in these patients were not significant and are not shown.

---

### Table III. Antibodies for IHC

| Primary antibody | Supplied by                  | Cell marker            | Dilution | Temperature | Incubation period |
|------------------|------------------------------|------------------------|----------|-------------|------------------|
| CD3              | Novocastra Laboratories Ltd. | T cell                 | 1:100    | 20°C        | 120 min          |
| CD4              | Novocastra Laboratories Ltd. | helper T cell          | 1:25     | 4°C         | 24 hr            |
| CD8              | Novocastra Laboratories Ltd. | cytotoxic T cell       | 1:50     | 20°C        | 90 min           |
| CD20             | Novocastra Laboratories Ltd. | B cell                 | 1:100    | 20°C        | 90 min           |
| CD56             | Zymed Laboratories           | NK cell                | 1:50     | 20°C        | 90 min           |
| S100             | Zymed Laboratories           | dendritic cell         | 1:50     | 20°C        | 90 min           |
| CD68             | Zymed Laboratories           | macrophage, monocyte   | 1:100    | 20°C        | 90 min           |
| AE1 and AE3      | DakoCytomation               | epithelial cell        | 1:100    | 20°C        | 90 min           |
Comparison of SARS and non-SARS cases

All confirmed SARS cases had similar pathologic changes in the lungs and lymphoid organs that differed only in severity. The severity of damage to the immune system and the extent of pulmonary damage and fibrosis corresponded with the duration of the disease, as counted from the onset of symptoms. In contrast, the suspected, but unconfirmed, cases demonstrated a wide range of pathology that varied with the etiology of each case. In three cases, the pathologic changes in the lungs were similar to those seen in the confirmed cases of SARS. However, the edema, consolidation, hyaline membrane formation, and fibrosis were less prominent, and there was no damage to the pulmonary epithelial cells. Multiple organ infection was a characteristic feature for confirmed cases of SARS, but not for the other patients. The damage to the immune system was found only in the patients who had SARS, but not in patients who had similar symptoms but did not harbor the virus. Neuronal changes with demonstrated SARS virus infection were unique to patients who had SARS, and were not found in the misdiagnosed cases. All controls used in SARS assays were negative, and thereby established the specificity of in situ hybridization and immunohistochemistry procedures. Additional controls, including those for the double labeling, excluded the possibility of interference between the in situ hybridization and the immunohistochemical reactions when performed in combination.

Figure 3. SARS pathology in the gut, kidney, and brain. (A) Depletion of mucosal lymphoid tissue of the small intestine of a patient who had SARS, showing decreased number of lymphocytes and depletion of germinal center. Bar, 200 μm. (B) EM image of a portion of mucosal cell in the small intestine of a SARS autopsy. M, microvilli; N, nucleus. The area indicated by the white arrow is enlarged in C. Bar, 2 μm. (C) Higher magnification of a SARS virus–containing vesicle (white arrow) in the same cell as shown in B. Bar, 0.2 μm. (D) In situ hybridization detected SARS sequence positive signal (arrows) in the cytoplasm of lymphocytes in the submucosal lymphoid tissue. Bar, 30 μm. (E) Negative control for in situ hybridization of SARS genomic sequence of the lymphocytes in the submucosal lymphoid tissue, in which an unrelated probe was used. No positive signal was detected. Bar, 30 μm. (F) In situ hybridization of SARS genomic sequence of lymphocytes in the submucosal lymphoid tissue of a patient who did not have SARS. No positive signal was detected. Bar, 30 μm. (G) In situ hybridization showing SARS-CoV positive signals (arrows) in the cytoplasm of a few mucosal epithelial cells in the small intestine of a patient who had SARS. Bar, 100 μm. (H) Negative control for in situ hybridization of SARS genomic sequence of mucosal epithelial cells in the submucosal lymphoid tissue, in which an unrelated probe was used. No positive signal was detected. Bar, 100 μm. (I) In situ hybridization of SARS genomic sequence of mucosal epithelial cells in the small intestine of a patient who had SARS, in which an unrelated probe was used. No positive signal was detected. Bar, 100 μm. (J) In situ hybridization detected SARS genomic sequence in the tubular epithelium (arrows) of the distal tubules of the kidney of a patient who had SARS. Bar, 70 μm. (K) Negative control for in situ hybridization of SARS genomic sequence of the distal tubules of the kidney of a patient who had SARS, in which an unrelated probe was used. No positive signal was detected. Bar, 70 μm. (L) In situ hybridization of SARS genomic sequence of the distal tubules of the kidney of a patient who did not have SARS. No positive signal was detected. Bar, 70 μm. (M) EM image of the cytoplasm of a tubular epithelial cell in the kidney of a patient who had SARS. The area indicated by the arrow is enlarged in N. M, microvilli of a tubular epithelial cell. Bar, 1 μm. (N) Enlargement of M. EM image of clusters of SARS virus-like particles (arrows) were detected in the cell. Bar, 0.2 μm. (O) In situ hybridization detected SARS genomic sequence in the cytoplasm of numerous neurons (arrows) in the brain of a patient who had SARS. Bar, 100 μm. (P) Negative control for in situ hybridization of SARS genomic sequence of neurons in the brain of a patient who had SARS in which the specific probe was not used. No positive signal was detected. Bar, 100 μm. (Q) In situ hybridization of SARS genomic sequence of neurons in the brain of a patient who did not have SARS. No positive signal was detected. Bar, 100 μm.
cyte damage is the hallmark of SARS. Administration of glucocorticoids contributed to a decrease in lymphocyte counts in both groups of patients; however, the difference in counts between the two groups persisted after glucocorticoid therapy. It was reported that lymphopenia is one of the earliest changes, and is a reliable prognostic predictor in SARS (13–18). An extensive literature search has not revealed a report of any other type of pneumonitis producing such severe lymphopenia. As the only logical explanation for the early and consistent lymphopenia that is demonstrated in patients who have SARS, we suggest that lymphocytes—particularly T lymphocytes—are infected and destroyed by the virus or by other immune cells. Our study provides evidence of infection and destruction of lymphocytes in the spleen, lymph nodes, and lymphoid tissues of the gut. In these sites lymphocytes were reduced markedly, germinal centers were depleted of lymphocytes, and in situ hybridization detected SARS viral positivity in the residual immune cells in the spleen and in circulation. This destruction of lymphocytes would cause an acute immunodeficiency that would aggravate the infection of the respiratory tract. The markedly weakened immune system at the early and mid stages of the disease is likely to be the reason for the acute nature and severity of the respiratory syndrome in SARS viral infection. SARS at various time points after the onset of symptoms and who were treated with glucocorticoids (confirmed SARS, n = 50; misdiagnosed cases, n = 20). The lymphocytes were decreased in both groups. However, the differences in the two groups with regard to the extent of lymphocyte reduction remained the same. The results from the retrospective investigation suggest that lymphopenia is a characteristic feature of SARS, and implicates an early and consistent destruction of lymphocytes.

Previously, there were reports that immune overreaction played a role in the immune injury and pathogenesis of SARS. However, there has been no concrete evidence to support this notion. The data on lymphokine production in SARS was not conclusive, and there was no report of a uniform and consistent increase of lymphocytes in those patients. The release of respiratory symptoms following steroid treatment (19) could be attributed to the antiinflammatory effect of the therapies, rather than immune suppression. Although the role of immune hyperreaction, particularly in the early phase of the disease, could not be ruled out completely, the evidence that we obtained points more to a direct immune injury as an important component in SARS pathology and pathogenesis.

The pathologic changes in the digestive tract, and the direct viral infection of mucosal epithelial cells and lymphoid tissue in the mucosa and the submucosa of small and large intestines, provide an explanation for the presence of the virus in the stool of patients who have SARS. Approximately 29% to 39.2% of patients who have SARS have diarrhea and other digestive tract symptoms, and these symptoms occurred ∼3.5–7.5 d after the onset of fever (15, 16). This period likely is required for the virus to infect the immune cells that circulate to attack and damage the gut. The continued

Figure 4. Lymphocyte subtypes in patients who had confirmed or misdiagnosed SARS. (A–C) The cell counts of CD3, CD4 and CD8, respectively, at various time points after the onset of symptoms in patients who were not treated with glucocorticoids. The data indicate that the lymphocytes were decreased from the onset of the disease in patients who had SARS but not in patients who did not have SARS (confirmed SARS, n = 15; misdiagnosed cases, n = 15). D, E, and F show the cell counts of CD3, CD4, and CD8, respectively, in patients who had confirmed or misdiagnosed SARS at various time points after the onset of symptoms and who were treated with glucocorticoids (confirmed SARS, n = 50; misdiagnosed cases, n = 20).
shedding of the mucosal epithelial cells and the damaged submucosal lymphocytes most likely are the source for the virus in the stool. Because SARS-infected epithelial cells were not found in the stomach and esophagus, it suggests that the virus is not ingested but more likely is presented to the gut by way of infected circulating immune cells. Reports that demonstrated SARS in the small and large intestine support this hypothesis (20).

The selective infection of the distal renal tubules provides an explanation for the presence of the virus in the urine, and perhaps for hematuria that may occur in patients who have SARS (15, 16). The Vero E6 cells that were used to identify and isolate the SARS coronavirus were derived from the renal epithelial cells of the green monkey (21); this suggests that kidney epithelial cells are inherently vulnerable to SARS infection.

Infection of neurons seemed to occur in only selected areas of the brain in all eight cases. The scattered red degeneration of the neurons is a sign of neuronal hypoxia/ischemia. The observation of virus in neurons may provide an explanation for the higher than usual incidence of neuronal and psychologic abnormalities that are seen in patients who have late-stage SARS (22, 23). These neurologic symptoms previously were attributed to negative social pressure during the epidemic.

**Postulated pathogenesis of SARS**

Based on our findings, we propose the following pathogenesis mechanism of SARS. The SARS virus enters the body through the respiratory tract and first infects the epithelial cells of the trachea, bronchi, bronchioles, and lungs. The virus infects resident, infiltrating, and circulating immune cells. The circulating immune cells carry the virus to other organs. The virus infects and damages the immune cells of the spleen, peripheral and central lymph nodes, and other lymphoid tissues. The immune defense is weakened significantly, which leads to rapid deterioration of the pneumonia. In the same manner, the blood-borne SARS virus infects other organs. As such, patients who have compromised immune function, such as those who have chronic diseases and aged individuals, suffer a more severe illness and have a much higher mortality from SARS (15). The extent of immune cell damage, reflected by lymphocyte count, is a manifestation of the patient’s immune status and a predictor of outcome. The damage to the immune system, more than damage to the lungs, determines whether a patient recovers or dies from the infection. In a way, the name “sudden acute respiratory syndrome” is inappropriate because it diverts attention from the primary pathologic changes that result from SARS virus infection. It must be emphasized that immune damage most likely is the primary determinant of clinical outcome.

This study unveils a hitherto unknown, but significant, aspect of the pathogenesis of SARS. Our proposed mechanism of infection and dissemination is capable of explaining all of the clinical symptoms and laboratory findings that have been reported for SARS. It provides a comprehensive theory of pathogenesis for this new disease. In a way, SARS infection is similar to HIV infection that causes AIDS. Although HIV attacks and destroys the target cells slowly, particularly lymphocytes (24), SARS virus infects and destroys the immune cells in a much faster and more devastating fashion. Like many other infectious diseases, SARS infections show differing degrees of severity in different individuals. Only the most severe cases demonstrate the full range of pathologic changes that was described above. Our findings suggest that body fluid and fecal–respiratory tract transmission of the virus, although not reported, is possible because SARS viruses or its sequences are detectable in the blood, intestines, stool, and urine. A correct understanding of the pathogenesis is crucial for developing animal models to test effective vaccines and to establish techniques for early diagnosis. Further detailed studies of the immune damage will shed more light on the true nature of the pathogenesis of SARS.

**MATERIALS AND METHODS**

Autopsies were performed on 18 patients who were suspected to have died of SARS infections; 15 died between June and August 2003 (7 confirmed as SARS) and 3 died in April 2004 (one confirmed as SARS). The World Health Organization’s diagnostic criteria for SARS (25) were used for clinical diagnoses. These included SARS contact history, sudden onset of high fever, respiratory symptoms, chest X-ray findings, and unresponsiveness to antibiotic therapy. The clinical data on the 18 autopsied cases is presented in Table IV. Retrospective analysis of suspected SARS cases provided a comparison between true and misdiagnosed SARS cases. The confirmation of SARS infection was made by real-time RT-PCR demonstration of the SARS virus-specific sequence in blood or tissue samples or SARS antibody positivity in the sera of the patients. Cases were considered to represent a misdiagnosis when repeated testing for SARS-specific antibody was negative (each case tested at least twice, with tests 2 wk apart). The misdiagnose rate in one of our hospitals was ~35%. These patients were admitted to the hospital because of SARS-like symptoms, and in the initial period of the SARS epidemic, specific antibody tests and SARS genomic sequence detection were not available for confirmation. Misdiagnosed cases were treated similarly to confirmed cases of SARS. Autopsy tissue samples from 6 age-matched and otherwise healthy subjects who died of head trauma served as controls.

Procedures for histopathologic investigation of the autopsies for LM and EM were those performed routinely in laboratories as described previously (26, 27). The technique of in situ hybridization was based on Zhang et al. (28). In brief, a sequence of 154 bp was amplified by polymerase chain reaction from the SARS coronavirus genome sequence. These sequence data are available from GenBank/EMBL/DDJB under accession no. AY274119. The RNA probe was prepared by in vitro transcription in the presence of digoxigenin-UTP. The in situ hybridization reaction was performed on formalin-fixed, and paraffin-embedded tissue sections with the SARS probe at 50 μg/ml. The hybridization cocktail was incubated at 55°C for 16 h. The alkaline phosphatase-labeled antidigoxigenin antibody (1:500) was incubated for 60 min, and colorization was achieved with nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate and counterstained with methyl-green. Immunoelectron microscopy was based on the technique of Goldsmith et al. (29). The EM in situ hybridization technique was based on Vandell et al. (26). In brief, the in situ hybridization reaction was performed on the tissue grids in a procedure similar to that for the LM. The labeled probe was detected with colloidal gold (10 nm)-labeled antibody to digoxigenin. Immunohistochemistry was performed using a range of monoclonal antibodies to identify the different cell types that were infected or affected by the virus (Table I). Immunohistochemistry was performed as described by Lin et al. (30), and antigen retrieval technique was performed as described previously (31, 32). Real time RT-PCR was performed with the technique of Wu et al. (33). In brief,
Table IV. Clinical data for 18 suspected SARS cases

| Case no. | Age/gender | Course | Clinical symptoms | Chest radiograph | Lymphopenia | SARS pathogen (real-time PCR) | History | Steroid treatment | Diagnosis |
|----------|------------|--------|-------------------|------------------|------------|-------------------------------|---------|------------------|-----------|
| 001      | 51/male    | 45     | fever and cough   | infiltrates in the right lower portion of the lung | yes        | yes                           | healthy | +                | SARS      |
| 003      | 50/male    | 33     | fever, cough, and shortness of breath | bilateral ground-glass changes | yes        | yes                           | coronary heart disease, primary hypertension | -      | SARS            |
| 005      | 31/male    | 35     | fever and nonproductive cough | ground-glass changes in periphery of left lower and right middle lobes | yes        | yes                           | non-Hodgkin's lymphoma | +      | SARS            |
| 006      | 49/female  | 32     | fever and shortness of breath | interstitial infiltrates | yes        | yes                           | no notable medical history | +      | SARS            |
| 008      | 24/male    | 21     | fever and cough   | bilateral patchy exudation in the lower lobes | yes        | yes                           | psychosis | +    | SARS            |
| 011      | 20/male    | 58     | fever and cough   | bilateral patchy interstitial infiltrates in lower lobes | yes        | yes                           | healthy | +    | SARS            |
| 015      | 58/male    | 62     | fever, cough, and chest distress | bilateral patchy ill-defined air-space shadowing | yes        | yes                           | chronic liver disease (hepatitis B), coronary heart disease | +    | SARS            |
| 018      | 52/female  | 16     | fever and nonproductive cough | infiltrates in the right lower portion of the lung | yes        | yes                           | bronchopulmonary tuberculosis | +    | SARS            |
| 002      | 38/male    | 1      | fever              | unknown          | no         | no                           | healthy | +    | anaphylactic shock |
| 004      | 40/male    | 35     | unknown            | no               | no         | no                           | duodenal ulcer   | +    | duodenal perforation |
| 007      | 40/male    | -      | unknown            | -                | unknown   | unknown                        | unknown     | unknown |
| 009      | 91/male    | 8      | fever and cough   | hydrothorax in the left pectoral cavity | yes        | no                           | chronic pulmonary tuberculosis, emphysema | +    | bronchopneumonia, tuberculosis |
| 010      | 30/male    | -      | fever and cough   | unknown          | no         | no                           | healthy | -    | suicide, hemorrhagic shock, interstitial pneumonia |
| 013      | 87/male    | 4–5 h  | fever and cough, diarrhea | unknown          | yes        | no                           | thrombosis in brain and logagnosia | -    | bronchopneumonia, emphysema |
| 014      | 36/male    | 1      | fever and headache | bilateral patchy interstitial infiltrates in lower lobes | yes        | no                           | healthy | +    | lobular pneumonia |
| 016      | 28/male    | 10     | fever and cough   | infiltrates in the right lower and left middle portion of the lung | yes        | no                           | healthy | +    | fibrinous hemorrhagic pneumonia |
| 017      | 59/male    | 10     | fever, cough, and shortness of breath | bilateral interstitial infiltrate with reticulonodular pattern | yes        | no                           | healthy | -    | confluent bronchopneumonia |
| 019      | 43/female  | 2      | fever and diarrhea | bilateral focal consolidation of the lung | yes        | no                           | anemia | +    | confluent bronchopneumonia, serous-fibrinous pericarditis |

total RNA was extracted from clinical samples using Trizol reagents according to the manufacturer’s instructions. 1 μg of total RNA was transcribed into cDNA with the superscript first-strand cDNA synthesis system. Taqman real-time quantitative PCR was conducted according to the manufacturer’s instructions (Applied Biosystems). Three pairs of primers were designed and constructed (Genbank G130027616 [15121–15661]). The designs of the primers and the probes that were used for real-time PCR and in situ hybridization were those described previously (33). They were 5’-GCCCAAG-TATTAAGTGGAGT-3’ and 5’-GAAGTGACATTTACATTGCTA-3’ as the innermost pair; 5’-ACACTTGCTGTAACCTATCAC-3’ and 5’-TCATAGAGCGGTGTTGAG-3’ as the outer pair; and 5’-CTAACATGCCTAGGATATAAG-3’ and 5’-CAGTGACAGTGACTATCCAC-3’ as the outermost pair. The molecular beacon technique was used (33). The sensitivity and specificity of this standardized real-time RT-PCR assay for the detection of SARS-CoV in postmortem lung tissues were established previously (34).

To identify the cell types that were infected by the virus, double labeling was performed by combining in situ hybridization for SARS viral genomic sequences and immunohistochemistry for one of the cell-associated markers. The in situ hybridization signal was visualized with alkaline phosphatase, which results in a dark blue color, whereas positive immunostaining signal was visualized with diamenobenzodin, which gives a reddish-brown color. When the two signals are present in the same cell, the staining changes to a purplish color, which is easily distinguishable from either of the primary colors. In addition, in situ hybridization and immunohistochemistry were performed separately on consecutive sections to analyze the relationship between in situ hybridization signals and immunostaining signals to ascertain the cell types that were infected by the virus. Seven cell marker antigens were examined to identify epithelial cells, macrophages, T cells, B cells, and splenic dendritic cells. The specificities and the sources of these antibodies are shown in Table III.

Controls for immunohistochemistry included the omission of the primary antibody or using normal mouse serum in place of the primary antibody. Controls for in situ hybridization included the application of an unrelated probe and a probe that is identical, instead of complementary, to the sequence of the SARS genomic target. Aside from the controls that were described above for the two techniques, additional controls were performed for the double staining, including in situ hybridization and immunostaining.
alone, to ensure that one reaction did not interfere, diminish, or enhance the reaction of the other.

Because the pathology of the autopsy cases represents the mid and the late stages of the disease, the peripheral blood samples were taken from 22 patients who had confirmed SARS at 3 to 16 d after the onset of high fever to study relatively early changes. Blood samples from 4 patients who did not have SARS were examined as controls. 100 white blood cells per patient were examined with a transmission electron microscope (Jeol - JEM-100CX II) operating at 100 kW.

In addition, the lymphocyte counts from 65 patients who had confirmed SARS—50 of whom were treated with steroids (glucocorticoid 30 µg/kg) and the other 15 were not treated—and 35 patients who had misdiagnosed cases—20 of whom were treated with steroids and the other 15 were not treated—were analyzed retrospectively. The identification of confirmed SARS—50 of whom were treated with steroids (glucocorticoid 30 µg/kg) and the other 15 were not treated—and 35 patients who had misdiagnosed cases was achieved by the SARS antibody test described above.

The study was approved by the Institutional Science Committee of the Health Science Center, Peking University.

We are grateful to all of the front-line physicians and health care workers who cared for the patients, performed tests, and collected data for this study. We are indebted to our colleagues who were infected by the virus while performing their duties. Two lost their lives, and this article is dedicated to them. We also thank all members of the pathogenesis study team, some of whom risked SARS infection in performing the autopsies and collecting the samples.

This study was supported by grants from Peking University and the Ministry of Science and Technology, P.R. China entitled "Histopathology, tissue collection and the pathogenesis study team, some of whom risked SARS infection in performing the autopsies and collecting the samples."

REFERENCES

1. Peiris, J.S., K.Y. Yuen, A.D. Osterhaus, and K. Stohr. 2003. The severe acute respiratory syndrome. N. Engl. J. Med. 349:2431–2441.

2. World Health Organization. Communicable Disease Surveillance & Response (CSR). Severe Acute Respiratory Syndrome (SARS). Available at: http://www.who.int/csr/sars/en (accessed July 11, 2005).

3. To, K.F., J.H. Tong, P.K. Chan, F.W. Au, S.S. Chim, K.C. Chan, J.L. Cheung, E.Y. Liu, G.M. Tse, A.W. Lo, et al. 2004. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. J. Pathol. 202:157–163.

4. Peiris, J.S., S.T. Lai, L.L. Poon, Y. Guan, L.Y. Yam, M.T. Cheung, et al. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 361:1319–1325.

5. Chan-Yeung, M., and W.C. Yu. 2003. Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report. BMJ. 326:850–852.

6. Ding, Y., H. Wang, H. Shen, Z. Li, J. Geng, H. Han, J. Cai, X. Li, W. Kang, D. Weng, et al. 2003. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J. Pathol. 200:282–289.

7. Holmes, K.V. 2003. SARS coronavirus: a new challenge for prevention and therapy. J. Clin. Invest. 111:1605–1609.

8. Farcas, G.A., S.M. Poutanen, T. Mazzulli, B.M. Willey, J. Butany, S.L. Asa, P. Faure, P. Akhavan, D.E. Low, and K.C. Kain. 2005. Fatal severe acute respiratory syndrome is associated with multivisceral involvement by coronavirus. J. Infect. Dis. 191:193–197.

9. Shi, X., E. Gong, D. Gao, B. Zhang, J. Zheng, Z. Gao, Y. Zhong, W. Zou, B. Wu, W. Fang, et al. 2005. Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases. Am. J. Gastroenterol. 100:169–176.

10. Lee, N., D. Hui, A. Wu, P. Chan, P. Cameron, G.M. Joynt, A. Ahuja, M.Y. Yung, C.B. Leung, K.F. To, et al. 2003. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 348: 1986–1994.

11. Fooks, T.J., P.Y. Chong, P. Chiu, J.R. Galvin, R.M. Lourens, A.H. Reid, E. Selbs, C.P. McEvoy, C.D. Hayden, J. Fukuoka, et al. 2003. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum. Pathol. 34:743–748.

12. Lang, Z., L. Zhang, S. Zhang, X. Meng, J. Li, C. Song, L. Sun, and Y. Zhou. 2003. Pathological study on severe acute respiratory syndrome. Chin. Med. J. (Engl). 116:976–980.

13. Lu, H., X. Xu, Y. Lei, Y. Wu, B. Chen, F. Xio, G. Xie, and D. Han. 2005. Clinical features of probable severe acute respiratory syndrome in Beijing. World J. Gastroenterol. 11:2971–2974.

14. Booth, C.M., L.M. Matukas, G.A. Tomlinson, A.R. Rachlis, D.B. Rose, H.A. Dwoosh, S.L. Walmley, T. Mazzulli, M. Avendano, P. Derkach, et al. 2003. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 298:2801–2809.

15. Peiris, J.S., C.M. Chu, V.C. Cheng, K.S. Chan, I.F. Hung, L.L. Poon, K.I. Law, B.S. Tang, T.Y. Hon, C.S. Chan, et al. HKU/UCH SARS Study Group. 2003. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 361:1767–1772.

16. Hon, K.L., C.W. Leung, W.T. Cheng, P.K. Chan, W.C. Chu, Y.W. Kwan, A.M. Li, N.C. Fong, P.C. Ng, M.C. Chu, et al. 2003. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet. 361:1701–1703.

17. Cui, W., Y. Fan, W. Wu, F. Zhang, J.Y. Wang, and A.P. Ni. 2003. Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome. Clin Infect Dis. 37:857–859.

18. Li M.H., X.H. Li, X.W. Li, M. Li, Y.Y. Jiang, J.P. Dong, and W.L. Li. 2004. Difference and significance of T-lymphocyte subsets in differential diagnosis between severe acute respiratory syndrome and common atypical pneumonia. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 18:137–141.

19. Tuosto, L., E. Cundari, M.S. Montani, and E. Piccolrella. 1994. Analysis of susceptibility of mature human T lymphocytes to dexamethasone-induced apoptosis. Eur. J. Immunol. 24:1061–1066.

20. Leung, W.K., K.F. To, P.K. Chan, H.L. Chan, A.K. Wu, N. Lee, K.Y. Yuen, and J.J. Sung. 2003. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 125:1011–1017.

21. Marra, M.A., S.J. Jones, C.R. Astell, R.A. Holt, A. Brooks-Wilson, Y.S. Butterfield, J. Khattrı, J.K. Asano, S.A. Barber, S.Y. Chan, et al. 2003. The genome sequence of the SARS-associated coronavirus. Science. 300:1394–1400.

22. Yang, S.L., L.J. Liu, L. Dai, C. Zhang, J.T. Li, C. Chen, and H. Liu. 2003. Analysis of anxiety in 78 SARS patients. Nanfang Journal of Nursing. 10:27–28.

23. Du, L., J. Zhao, Y. Shi, Y. Xi, G.G. Zheng, Y. Yi, and W.P. He. 2003. A report of 4 cases of severe acute respiratory syndrome patients with suicide tendency. Academic Journal of Second Military Medical University. 24:636–637.

24. Pantaleo, G., C. Graziosi, J.F. Demarest, L. Butini, M. Montroni, C.H. Fox, J.M. Orenstein, D.P. Kotler, and A.S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 362:355–358.

25. World Health Organization. May 1, 2003. Case definitions for surveillance of severe acute respiratory syndrome (SARS). Available at: http://www.who.int/csr/sars/casedefinition/en/.

26. Vandelli, I.M., F.T. Tapia, L. Probert, A.M. Buchan, J. Gu, J. de Mey, S.R. Bloom, and J.M. Polak. 1982. Immunogold staining procedure for the localization of regulatory peptides. Peptides. 3:1–13.

27. Lossi L., P. Ainar, E. Beltramino, and A. Merighi. 2002. Immunogold labeling techniques for transmission electron microscopy: applications in cell and molecular biology. In Gold and Silver Staining Techniques in Molecular Morphology. G.W. Hacker and J. Gu, editors. CRC Press, Boca Raton, FL. 147–167.

28. Zhang, B., J. Zheng, E.C. Gong, Z.F. Gao, Y.F. Zhong, L. Hou, H.H. Zhong, Z.G. Xie, H.Q. Shao, D.X. Gao, et al. 2003. Detection of SARS coronavirus in human tissues by in situ hybridization. Appl...
29. Goldsmith, C.S., K.M. Tatti, T.G. Kuszak, P.E. Rollin, J.A. Comer, W.W. Lee, P.A. Rota, B. Bankamp, W.J. Bellini, and S.R. Zaki. 2004. Ultrastructural characterization of SARS coronavirus. Emerg. Infect. Dis. 10:320–326.

30. Lin, Y., X. Shen, R.F. Yang, Y.X. Li, Y.Y. Ji, Y.Y. He, M.D. Shi, W. Lu, T.L. Shi, J. Wang, et al. 2003. Identification of an epitope of SARS-coronavirus nucleocapsid protein. Cell Res. 13:141–145.

31. Gu, J., M. Forte, H. Hance, N. Carson, C. Xenachis, and R. Rufner. 1994. Microwave fixation, antigen retrieval, and accelerated immunocytochemistry. Cell Vis. 1:76–77.

32. Shi, S.R., J. Gu, J.F. Turrens, R.J. Cote, and C.R. Taylor. 2000. Development of AR technique: philosophy and theoretical base. In Antigen Retrieval. S.R. Shi, J. Gu, C.R. Taylor, editors., Eaton Publishing Co. Natick, MA. 17–39.

33. Wu, B.Q., H.H. Zhong, J.P. Gao, S.P. Liu, W.J. Heng, W. Ao, and J. Gu. 2003. Gene detection of severe acute respiratory syndrome-related coronavirus. Chinese Journal of Pathology. 32:212–214.

34. Mazzulli, T., G.A. Farca, S.M. Poutanen, B.M. Willey, D.E. Low, J. Butany, S.L. Asa, and K.C. Kam. 2004. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg. Infect. Dis. 10:20–24.